Skip to content

Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women

Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women: a Randomized, Double-blind Controlled Trial

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02838576
Enrollment
72
Registered
2016-07-20
Start date
2017-03-01
Completion date
2020-12-31
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthralgia

Brief summary

Arthralgia has been a common complaint in postmenopausal period which seems to be involved with estrogen depletion, although, its pathophysiology isn´t completely clarified. It seems to relate with the level of physical activity, climacteric symptoms and pain catastrophizing. In view of the multiple dimensions involved in arthralgia in postmenopausal women which characterize it as a complex phenomenon, this study aims to describe the effects of hormone replacement therapy in women aged between 45 and 55 years, considering estrogen as a possible anti-nociceptive factor.

Detailed description

This study is a randomized double-blind controlled clinical trial with postmenopausal women aged between 45 and 55 years with chronic arthralgia related to climacteric. They will be evaluated climacteric symptoms, pain intensity, level of physical activity, pain catastrophising, depression, anxiety, quality of sleep and quality of life. The volunteers will be randomized, in the proportion 1:1, to treatment with either 0,625 mg conjugated equine estrogen, via oral administration, for 12 weeks or placebo, via oral administration, for 12 weeks. The randomization will be performed by a computer-generated random numbers list. The investigators will be blinded until completion of 12 weeks. Evaluation of climacteric symptoms, pain intensity, level of physical activity, pain catastrophising, depression, anxiety, quality of sleep and quality of life will be performed in the hospital at baseline, 1, 2, 3, 6 months and 15 days. In each visit, participants will be evaluated about adverse effects such as diarrhea, nausea and vomit.

Interventions

Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.

DRUGPlacebo

Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* age between 45 and 55 years * chronic arthralgia related to climacteric * regular mammography and pap smear test in the last twelve months * availability to attend hormone replacement therapy * maximum of ten years of amenorrhea according to the criteria of Stages of Reproductive Aging Workshop (STRAW) * without use of hormone replacement therapy, at least, previous six months * no contraindication to hormone replacement therapy (current or past of breast and / or cervical cancer, severe current or recent heart disease, thromboembolism, hypertension with no control, metabolic diseases (but stable thyroid disease) and endometrial hyperplasia to be enlightened * Informed consent

Exclusion criteria

* autoimmune diseases * visceral pain (chronic pelvic pain, dyspareunia, irritable bowel syndrome) * systemic diseases (rheumatic, neurological, oncology, sexually transmitted infection) * body mass index of 30 or greater * soy diet * abuse of alcohol and drugs * large surgeries

Design outcomes

Primary

MeasureTime frameDescription
Arthralgia6 monthsArthralgia´ll be measured by numeric scale (0-10).

Secondary

MeasureTime frameDescription
Level of physical activity6 monthsLevel of physical activity´ll be evaluated by International Physical Activity Questionnaire - Brazilian Version whose three levels of physical activity are low, moderate and high.
Pain Catastrophizing6 monthsPain Catastrophizing´ll be evaluated by Pain Catastrophizing - Brazilian Version into three subscales being magnification, rumination, and helplessness. The higher the score, the more catastrophizing thoughts are present.
Health-related quality of life6 monthsQuality of life´ll be evaluated by Women´s Health Questionnaire - Brazilian Version (somatic symptoms, depressed mood, cognitive difficulties, anxiety and fear, sexual functioning, vasomotor symptoms, sleep problems, menstrual problems, and self-perceived attraction). The higher the score, the more pronounced the suffering and dysfunction.
Climacteric symptoms6 monthsClimacteric symptoms´ll be evaluated by Menopause Rating Scale - Brazilian Version. The score increases point by point with increasing severity of subjectively perceived symptoms in each of the 11 items.
Anxiety6 monthsAnxiety´ll be evaluated by Beck Anxiety Inventory - Brazilian Version. The standard cut-off scores are minimal, mild, moderate and severe depression.
Quality of sleep6 monthsQuality of sleep´ll be evaluated by Pittsburgh Sleep Quality Index - Brazilian Version. Lower scores denote a healthier sleep quality.
Depression6 monthsDepression´ll be evaluated by Beck Depression Inventory - Brazilian Version. The standard cut-off scores are minimal, mild, moderate and severe depression.

Countries

Brazil

Contacts

Primary ContactMaria Celeste Osório Wender, Ph.D
mceleste@ufrgs.br55 51 3359-8117
Backup ContactFernanda Vargas Ferreira, Ph.D
fernandaferreira@unipampa.edu.br55 51 3359-8117

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026